PET Neurology Market - Strategic Insights and Forecasts (2026-2035)

The Global PET Imaging in Neurology Market is forecasted to reach USD 2.45 billion by 2035. This represents a substantial growth at a Compound Annual Growth Rate (CAGR) of 6.5% from its 2026 valuation of USD 1.38 billion, as detailed in the report.

Rising Alzheimer's disease prevalence is significantly increasing demand for amyloid and tau PET imaging. The report highlights that specialized radiotracers are also crucial for identifying dopaminergic dysfunction, neuroinflammation, and abnormal glucose metabolism, which are vital for accurate differential diagnosis and disease staging in neurological disease management.

The market's expansion is primarily driven by the growing burden of neurodegenerative diseases, necessitating earlier and more accurate diagnosis. Additionally, the increasing implementation of precision neurology initiatives and intensified research activity into disease-specific neurological biomarkers are accelerating the adoption and utilization of advanced PET procedures.

PET imaging occupies a central position in advanced neurological care by providing objective biomarkers that improve diagnosis, treatment selection, and disease monitoring. It enables clinicians to visualize metabolic, biochemical, and molecular activity, detecting early molecular abnormalities before structural changes are visible, which is crucial for precision neurology and molecular diagnostics.

Increasing research activity is vital, with research institutions strengthening molecular imaging programs as neuroscience innovation focuses on disease mechanisms. Notably, neuroinflammation imaging research is creating new opportunities for advanced radiotracer development and supports translational neuroscience research, driving deeper understanding of disease progression.

Healthcare systems are expanding PET utilization due to the increasing neurological disease prevalence across aging populations. Furthermore, pharmaceutical companies are increasing PET utilization in neurological drug development programs, leveraging molecular diagnostics to support more accurate tools for differential diagnosis and disease staging.